The TP53 mutation frequency in this study is in line with the one reported by IARC in head and neck squamous cell carcinomas (57% in this study; 47.5% in IARC TP53 mutation database [19]. This evidence concerns the gene TP53 and head and neck squamous cell carcinoma.